Tokyo (JCN) - Daiichi Sankyo Co., Ltd. has announced that its subsidiary Daiichi Pharmaceutical Co., Ltd. has signed an agreement to acquire 100% of the shares of Seoul-based Daiichi Pharmaceutical Korea Co., Ltd. ('KDP'), a joint venture with Jeil Pharmaceutical Co., Ltd. The acquisition will take effect on October 13, when KDP becomes a wholly
owned subsidiary of Daiichi Pharmaceutical. With this acquisition, the Daiichi Sankyo Group plans to actively expand
its business operations throughout Asia.
Copyright(C) 2006 Japan Corporate News Network. www.japancorp.net All
>>> Discuss This Story